XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.

XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.
R
R

Regeneron

පුවත්

Reuters - සති 1කට පෙර

U.S. Amazon, IQVIA Holdings, Uber

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber Nov 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, IQVIA Holdings and Uber, on Friday. HIGHLIGHTS * Amazon AMZN.O : JP Morgan raises target price to $250 from $230 * Cheniere Energy Inc LNG.N : Raymond James raises target price to $225 from $210 * IQVIA Holdings Inc IQV.N : TD Cowen cuts target price to $255 from $270 * Regeneron Pharmaceuticals Inc REGN.O
A
A
C
E
I
K
R
A
A
E
G
U
A
A
A
I
Reuters - සති 1කට පෙර

U.S. Amazon, IQVIA Holdings, Uber

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber Nov 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, IQVIA Holdings and Uber, on Friday. HIGHLIGHTS * Amazon AMZN.O : JP Morgan raises target price to $250 from $230 * Cheniere Energy Inc LNG.N : Raymond James raises target price to $225 from $210 * IQVIA Holdings Inc IQV.N : TD Cowen cuts target price to $255 from $270 * Regeneron Pharmaceuticals Inc REGN.O
A
C
E
I
K
R
U
A
A
S
E
G
U
I
Reuters - සති 1කට පෙර

Regeneron Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary

Regeneron Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary Regeneron Pharmaceuticals Inc REGN.OQ reported quarterly adjusted earnings of $12.46​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of $11.59. The mean expectation of twenty four analysts for the quarter was for earnings of $11.69 per share.
R
Reuters - සති 1කට පෙර

Regeneron Pharmaceuticals Files For Mixed Shelf

BRIEF-Regeneron Pharmaceuticals Files For Mixed Shelf Oct 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PHARMACEUTICALS INC FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING Source text: [ID:n0001104659-24-113087] Further company coverage: REGN.O
R
Reuters - සති 1කට පෙර

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Xcel Energy Inc XEL.OQ +6.1% Booking Holdings Inc BKNG.OQ +4.7% Warner Bros Discovery Inc WBD.OQ +4.5% Comcast Corp CMCSA.OQ +3.1% Dollar Tree Inc DLTR.OQ +2.5% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -12.2% Regeneron Pharmaceuticals Inc REGN.OQ -9.8% IDEXX Laboratories Inc IDXX.OQ -8.9% Arm Holdings PLC ARM.OQ -8.4% Microsoft Corp MSFT.OQ -5.1% The Nasda
C
I
M
R
X
D
U
B
Reuters - සති 1කට පෙර

U.S. STOCKS Estee Lauder, DoorDash, Peloton Interactive

BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, DoorDash, Peloton Interactive Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Thursday, as warnings from Microsoft and Meta Platforms about soaring AI costs dampened enthusiasm for megacap stocks, which have led the market this year.
A
B
C
C
E
I
M
R
W
X
S
U
U
E
E
P
U
H
I
T
Reuters - සති 1කට පෙර

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Xcel Energy Inc XEL.OQ +6.8% Warner Bros Discovery Inc WBD.OQ +6.8% Booking Holdings Inc BKNG.OQ +5.3% Comcast Corp CMCSA.OQ +2.9% Cognizant Technology Solutions Corp CTSH.OQ +2.8% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -14.7% Regeneron Pharmaceuticals Inc REGN.OQ -9.6% IDEXX Laboratories Inc IDXX.OQ -9.0% Arm Holdings PLC ARM.OQ -8.5% Microsoft Corp MSF
C
C
I
M
R
X
U
B
Reuters - සති 1කට පෙර

Regeneron falls as higher dose version of eye drug misses sales expectations

BUZZ-Regeneron falls as higher dose version of eye drug misses sales expectations Updates ** Shares of drugmaker Regeneron Pharmaceuticals REGN.O fall 9.6% to $834.12, its lowest since December last year ** Regeneron reports Q3 sales of $392 million for the higher dose version of its eye drug Eylea, missing analysts' expectation for the second stra
R
Reuters - සති 1කට පෙර

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

UPDATE 1-Regeneron shares drop as higher-dose Eylea drug misses sales estimates Rewrites throughout to add details on higher dose version of Eylea By Christy Santhosh Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O o n Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.
B
R
R
S
Reuters - සති 1කට පෙර

Regeneron falls as higher dose version of eye drug misses sales expectations

BUZZ-Regeneron falls as higher dose version of eye drug misses sales expectations ** Shares of drugmaker Regeneron Pharmaceuticals REGN.O fall 1.9% to $904.99 premarket ** Regeneron reports Q3 sales of $392 million for the higher dose version of its eye drug Eylea, missing analysts' expectation of $417 million - LSEG data ** Co is trying upgrade pa
R
Reuters - සති 1කට පෙර

Regeneron beats results estimates on demand for eczema treatment, eye drug

Regeneron beats results estimates on demand for eczema treatment, eye drug Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff comp
B
R
R
S
Reuters - සති 1කට පෙර

Regeneron Reports Third Quarter 2024 Financial AND OPERATING RESULTS

BRIEF-Regeneron Reports Third Quarter 2024 Financial AND OPERATING RESULTS Oct 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS REGENERON PHARMACEUTICALS: QTRLY U.S. NET SALES FOR EYLEA HD & EYLEA INCREASED 3% VERSUS Q3 2023 TO $1.54 BILLION REGENERON PHARMACEUTICALS: QTRLY D
R
Reuters - සති 1කට පෙර

Regeneron Q3 Adjusted EPS USD 12.46 Vs. IBES Estimate USD 11.7

BRIEF-Regeneron Q3 Adjusted EPS USD 12.46 Vs. IBES Estimate USD 11.7 Oct 31 (Reuters) - Regeneron Q3 revenue USD 3,720 million vs. IBES estimate USD 3,670 million. Q3 EPS USD 11.54 outlook FY capex USD 700-740 million
R
Reuters - සති 1කට පෙර

Megacaps spooked, world bonds on edge

MORNING BID AMERICAS-Megacaps spooked, world bonds on edge A look at the day ahead in U.S. and global markets from Mike Dolan Cloudy outlooks from U.S. megacaps Microsoft and Meta combined with edgy government bond markets around the world to unsettle investors on Thursday, with the latest U.S. opinion polls showing next week's presidential election is no foregone conclusion.
A
A
C
E
I
M
M
R
U
U
X
A
J
U
U
U
U
E
E
I
W
B
E
H
Reuters - සති 1කට පෙර

What to Watch in the Day Ahead - Thursday, October 31

What to Watch in the Day Ahead - Thursday, October 31 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Analysts expect Apple to report a 5.5% growth in quarterly revenue for its fourth fiscal quarter.
A
A
C
I
I
R
E
U
Reuters - සති 2කට පෙර

What to Watch in the Week Ahead and on Monday, October 28

What to Watch in the Week Ahead and on Monday, October 28 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Ford is expected to report higher third-quarter revenue and profit, aided by sales of its commercial vehicles.
A
A
B
C
C
C
C
D
G
I
J
M
P
P
R
S
K
K
E
R
U
Reuters - සති 2කට පෙර

U.S. Coca-Cola, Nextera Energy Partners, ServiceNow

U.S. RESEARCH ROUNDUP-Coca-Cola, Nextera Energy Partners, ServiceNow Oct 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Coca-Cola, Nextera Energy Partners, and ServiceNow on Thursday. HIGHLIGHTS * Avery Dennison Corp AVY.N : JP Morgan cuts to neutral from overweight * Coca-Cola Co KO.N : JP Morgan cuts target price to $75 from $78 * Nextera Energy Partners LP NEP.N : JP Morgan raises to neutral from underweight *
A
A
A
B
C
D
D
E
E
N
R
C
L
T
E
E
I
S
T
A
A
E
E
G
H
L
R
Reuters - සති 2කට පෙර

Regeneron loses bid to block Amgen's Eylea biosimilar launch in US

UPDATE 1-Regeneron loses bid to block Amgen's Eylea biosimilar launch in US Adds comments from Regeneron and Amgen in paragraphs 3-4, additional context in paragraphs 5-8 By Blake Brittain Oct 22 (Reuters) - Amgen AMGN.O will launch its biosimilar version of Regeneron's REGN.O blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
A
R
Reuters - සති 2කට පෙර

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case By Blake Brittain Oct 22 (Reuters) - Amgen AMGN.O will launch its biosimilar version of Regeneron's REGN.O blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to temporarily block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
A
R
Reuters - සති 3කට පෙර

Three-Year Results For Eylea Hd (Aflibercept) Injection 8 Mg Demonstrate Continued Durable Vision Gains And Anatomic Improvements With Extended Dosing Intervals In Patients With Diabetic Macular Edema

BRIEF-Three-Year Results For Eylea Hd (Aflibercept) Injection 8 Mg Demonstrate Continued Durable Vision Gains And Anatomic Improvements With Extended Dosing Intervals In Patients With Diabetic Macular Edema Oct 18 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : THREE-YEAR RESULTS FOR EYLEA HD® (AFLIBERCEPT) INJECTION 8 MG DEMONSTRATE CONTINUED
R

තත්ත්වයන්

ජනප්‍රිය වත්කම්

වියාචනය: XM Group සමාගම් ක්‍රියාත්මක කිරීම පමණක් වන සේවා සපයන අතර වෙබ් අඩවියේ හෝ වෙබ් අඩවිය හරහා ලබා ගත හැකි අන්තර්ගතය බැලීමට සහ/හෝ භාවිත කිරීමට පුද්ගලයෙකුට ඉඩ සලසමින් අපගේ මාර්ගගත වෙළඳ පහසුකම වෙත ප්‍රවේශය ලබා දෙන අතර වෙනස් කිරීමට හෝ පුළුල් කිරීමට අදහස් නොකරයි. එවැනි ප්‍රවේශය සහ භාවිතය සෑම විටම (i) නියමයන් සහ කොන්දේසි, (ii) අවදානම් අනතුරු ඇඟවීම් සහ (iii) සම්පූර්ණ වියාචනයට යටත් වේ. එබැවින් එවැනි අන්තර්ගතයක් සාමාන්‍ය තොරතුරුවලට වඩා වැඩි යමක් සපයා නොමැත. විශේෂයෙන්ම, අපගේ මාර්ගගත වෙළඳ පහසුකමේ අන්තර්ගතය පෙළඹවීමක් හෝ මූල්‍ය වෙළඳපොළවල කිසිදු ගනුදෙනුවක් සිදු කිරීමට ඉදිරිපත් කිරීමක් නොවන බව කරුණාවෙන් සලකන්න. ඕනෑම මූල්‍ය වෙළඳපොළක වෙළඳාම් කිරීම ඔබේ ප්‍රාග්ධනයට සැලකිය යුතු අවදානමක් එක් කරයි.

අපගේ මාර්ගගත වෙළඳ පහසුකමේ ප්‍රකාශිත සියලු කරුණු අධ්‍යාපනික/තොරතුරුමය අරමුණු සඳහා පමණක් අදහස් කෙරෙන අතර මූල්‍ය, ආයෝජන බදු හෝ වෙළඳ උපදෙස් සහ නිර්දේශයන්; හෝ අපගේ වෙළඳ මිල පිළිබඳ වාර්තාවක්; හෝ ඕනෑම මූල්‍ය උපකරණයක ඉදිරිපත් කිරීමක් හෝ ඒ සඳහා පෙළඹවීමක්; හෝ විශේෂ ඉල්ලීමකින් තොරව ඔබ වෙත ලබා දෙන ලද මූල්‍ය ප්‍රවර්ධනයන් ලෙස නොසැලකිය යුතුය.

ඕනෑම තෙවන පාර්ශවීය අන්තර්ගතයක් මෙන්ම XM විසින් සකසන ලද අන්තර්ගතය එනම් අදහස්, පුවත්, පර්යේෂණ, විශ්ලේෂණ, මිල ගණන් සහ වෙනත් තොරතුරු හෝ මෙම වෙබ් අඩවියේ අන්තර්ගත තෙවන පාර්ශවීය වෙබ් අඩවි සඳහා සබැඳි සාමාන්‍ය වෙළඳපොළ විවරණයක් ලෙස "පවතින පරිදි" සපයා ඇති අතර එහි ආයෝජන උපදෙස් ඇතුළත් නොවේ. ඕනෑම අන්තර්ගතයක් ආයෝජන පර්යේෂණයක් ලෙස අර්ථ දක්වා ඇති ප්‍රමාණයට, ආයෝජන පර්යේෂණයේ ස්වාධීනත්වය ප්‍රවර්ධනය කිරීමට නිර්මාණය කර ඇති නෛතික අවශ්‍යතාවලට අනුකූලව අන්තර්ගතය සකසා නොමැති බවත් එලෙස අරමුණු කර නොමැති බවත් ඔබ සලකා පිළිගත යුතු අතර එබැවින් එය අදාළ නීති සහ රෙගුලාසි යටතේ අලෙවිකරණ සන්නිවේදනයක් ලෙස සලකනු ලැබේ. ඉහත සඳහන් තොරතුරු සලකා මෙතනින් ප්‍රවේශ විය හැකි, ස්වාධීන නොවන ආයෝජන පර්යේෂණ සහ අවදානම් අනතුරු ඇඟවීම පිළිබඳ අපගේ දැනුම්දීම ඔබ කියවා තේරුම් ගෙන ඇති බව සහතික කර ගන්න.

අවදානම් අනතුරු ඇඟවීම: ඔබේ ප්‍රාග්ධනය අවදානමේ පවතී. උත්තෝලිත (ලෙවරේජ්) නිෂ්පාදන සෑම දෙනාටම සුදුසු නොවිය හැකිය. කරුණාකර අපගේ අවදානම් අනාවරණය සලකා බලන්න.